Market Cap 1.02B
Revenue (ttm) 586.32M
Net Income (ttm) 27.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 51.92
Profit Margin 4.76%
Debt to Equity Ratio -4.64
Volume 705,800
Avg Vol 779,626
Day's Range N/A - N/A
Shares Out 301.81M
Stochastic %K 18%
Beta 0.19
Analysts Sell
Price Target $5.75

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indicatio...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
9, Rue de Bitbourg, Luxembourg, Luxembourg
Toffik72
Toffik72 Jul. 15 at 5:37 AM
$ALVO Swedish SEB bank believes it is possible that Alvotech could raise its full-year guidance when it reports its second-quarter results. https://www.placera.se/telegram/alvotech-seb-ser-mojlighet-till-prognoshojning-for-2026-20260714 Here the translated version from swedish: STOCKHOLM (Nyhetsbyrån Direkt) – SEB believes it is possible that biosimilar company Alvotech could raise its full-year guidance when it reports its second-quarter results, although the bank's base-case expectation is that the guidance will remain unchanged. SEB wrote this in a research note in which it raised its price target to SEK 85 (approximately USD 8.85) from SEK 65 (approximately USD 6.75), while reiterating its Buy recommendation. With competitive pressures easing, SEB sees room for a positive re-rating of the stock, which it expects to occur over the next 12–18 months. For the full year 2026, Alvotech's guidance calls for: Total revenue of USD 650–700 million Adjusted EBITDA of USD 180–220 million
1 · Reply
Toffik72
Toffik72 Jul. 14 at 8:29 PM
$ALVO Interview with the CEO. https://insights.citeline.com/generics-bulletin/leadership/interviews/alvotech-seeks-launch-momentum-from-renewed-fda-push-LUAY3BMQQJHH3OZ3Z5DD7Y4UDM/
1 · Reply
JohnTill
JohnTill Jul. 14 at 3:49 PM
$ALVO Still taking it slow and added 50% to the position just now at 3.20-3.22. There is still a long way to the flood of positive news in Dec.+ and into 2027 but do not want to risk not have any position prior to this period. Will we see the 2s again?
1 · Reply
diggs24
diggs24 Jul. 14 at 3:26 PM
0 · Reply
Luc7777
Luc7777 Jul. 10 at 1:38 PM
$ALVO number one explanation is toxicity of unrevealed sharedealing. Not for sure but studied so many times...
0 · Reply
diggs24
diggs24 Jul. 9 at 9:31 PM
$ALVO As promised
1 · Reply
JohnTill
JohnTill Jul. 9 at 3:08 PM
$ALVO For anyone who missed it and wondering about the weakness. The $108 million convertible bond carried a conversion price of $5.9224, set at a 25% premium over the $4.7379 reference price. The bond includes a reset provision that kicks in if any equity raise or private placement is done. The most common design for these Nordic/European-style "reset on capital raise" clauses is to re-strike the conversion price at the new offering price plus the original premium — so $3.75 × 1.25 = $4.6875. I am betting this is what has been done. These bondholders hedge, which means the reset forced them to short an additional ~3–4 million shares to get back to delta neutral at the lower strike. On top of that, the reset adds roughly 5 million shares of dilution to the $108 million convert. Overall, I view the added cash as a positive and still believe we see that $8 gap filled in 2027 but short term, this explains the weakness. As posted, I sold out in the 4s and very slowly buying back.
1 · Reply
katkus
katkus Jul. 8 at 6:20 PM
$ALVO diluting the stock, any details about the most recent offering
0 · Reply
Stocksman45
Stocksman45 Jul. 7 at 9:27 PM
$ALVO Shares Outstanding by Year Reporting Date Shares Outstanding End of 2022. ~212 million End of 2023. ~290 million End of 2024 ~312 million End of 2025 312.0 million After June 2026 offering 390.4 million
2 · Reply
diggs24
diggs24 Jul. 7 at 2:24 PM
$ALVO Think I'll start buying back in at $3.25. The pop was nice and unexpected but the continued bleed was not expected.
1 · Reply
Latest News on ALVO
Transactions of Managers and Closely Associated Persons

Jul 3, 2026, 4:01 PM EDT - 11 days ago

Transactions of Managers and Closely Associated Persons


Alvotech $152M Spot Secondary priced at $3.75

2026-06-16T11:08:35.000Z - 4 weeks ago

Alvotech $152M Spot Secondary priced at $3.75


Alvotech TBA Spot Secondary; price range $3.75-$undefined

2026-06-15T22:30:37.000Z - 4 weeks ago

Alvotech TBA Spot Secondary; price range $3.75-$undefined


Alvotech Transcript: UBS Virtual Generics and Biosimilars Day

Jun 10, 2026, 10:30 AM EDT - 4 weeks ago

Alvotech Transcript: UBS Virtual Generics and Biosimilars Day


Alvotech announces FDA acceptance of AVT16 BLA for review

2026-06-08T09:20:28.000Z - 5 weeks ago

Alvotech announces FDA acceptance of AVT16 BLA for review

TEVA


Alvotech resubmits AVT05 BLAs to FDA

2026-06-04T09:10:13.000Z - 5 weeks ago

Alvotech resubmits AVT05 BLAs to FDA

RDY TEVA


Main Results of 2026 Annual and Extraordinary General Meeting

Jun 3, 2026, 4:30 PM EDT - 5 weeks ago

Main Results of 2026 Annual and Extraordinary General Meeting


Alvotech to present at upcoming investor conferences in June

Jun 2, 2026, 4:30 PM EDT - 6 weeks ago

Alvotech to present at upcoming investor conferences in June


Alvotech Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Alvotech Earnings Call Transcript: Q1 2026


Alvotech Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Alvotech Earnings release: Q1 2026


Alvotech Slides: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Alvotech Slides: Q1 2026


Alvotech Q1 2026 Financial Results

May 6, 2026, 4:30 PM EDT - 2 months ago

Alvotech Q1 2026 Financial Results


Alvotech Announces a Change in its Executive Team

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Alvotech Announces a Change in its Executive Team


Alvotech files Annual Report with the SEC

Mar 30, 2026, 7:58 PM EDT - 3 months ago

Alvotech files Annual Report with the SEC


Alvotech Publishes 2025 Annual Report

Mar 30, 2026, 7:55 PM EDT - 3 months ago

Alvotech Publishes 2025 Annual Report


Alvotech price target lowered to $4 from $8 at Deutsche Bank

2026-03-24T12:50:32.000Z - 4 months ago

Alvotech price target lowered to $4 from $8 at Deutsche Bank


Alvotech price target lowered to $4 from $5 at Barclays

2026-03-24T09:37:15.000Z - 4 months ago

Alvotech price target lowered to $4 from $5 at Barclays


Alvotech price target lowered to $6 from $10 at UBS

2026-03-23T23:30:12.000Z - 4 months ago

Alvotech price target lowered to $6 from $10 at UBS


Alvotech price target lowered to $4 from $5 at Barclays

2026-03-23T18:55:10.000Z - 4 months ago

Alvotech price target lowered to $4 from $5 at Barclays


Alvotech Earnings Call Transcript: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Earnings Call Transcript: Q4 2025


Alvotech Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Annual report: Q4 2025


Alvotech Earnings release: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Earnings release: Q4 2025


Alvotech Slides: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Slides: Q4 2025


Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar 18, 2026, 6:15 PM EDT - 4 months ago

Alvotech Q4 2025 and Full Year 2025 Financial Results


Alvotech Announces Increase in Number of Own Shares

Feb 11, 2026, 11:00 AM EST - 5 months ago

Alvotech Announces Increase in Number of Own Shares


Alvotech Slides: SEB Nordic Seminar presentation

Jan 8, 2026, 7:00 AM EST - 6 months ago

Alvotech Slides: SEB Nordic Seminar presentation


Alvotech Secures Term Loan Facility of USD 100 Million

Dec 31, 2025, 4:30 PM EST - 6 months ago

Alvotech Secures Term Loan Facility of USD 100 Million


Changes in company's own shares

Dec 29, 2025, 2:40 PM EST - 7 months ago

Changes in company's own shares


Alvotech's Financial Calendar for 2026

Dec 22, 2025, 3:26 PM EST - 7 months ago

Alvotech's Financial Calendar for 2026


Alvotech Transcript: Investor Update

Dec 16, 2025, 12:00 PM EST - 7 months ago

Alvotech Transcript: Investor Update


Alvotech Press release: Investor Update

Dec 16, 2025, 12:00 PM EST - 7 months ago

Alvotech Press release: Investor Update


Alvotech initiated with an Underweight at Barclays

2025-12-08T21:25:13.000Z - 7 months ago

Alvotech initiated with an Underweight at Barclays


Alvotech price target lowered to $10 from $14 at Morgan Stanley

2025-12-03T11:53:22.000Z - 8 months ago

Alvotech price target lowered to $10 from $14 at Morgan Stanley


Alvotech announces European Commission approval for AVT03

2025-11-24T10:35:12.000Z - 8 months ago

Alvotech announces European Commission approval for AVT03


Alvotech Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 10:30 AM EST - 8 months ago

Alvotech Transcript: Jefferies London Healthcare Conference 2025


Alvotech price target lowered to $10 from $13 at UBS

2025-11-18T14:36:54.000Z - 8 months ago

Alvotech price target lowered to $10 from $13 at UBS


Alvotech Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Alvotech Earnings Call Transcript: Q3 2025


Alvotech Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Alvotech Earnings release: Q3 2025


Alvotech Slides: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Alvotech Slides: Q3 2025


Alvotech price target lowered to $10 from $28 at Northland

2025-11-04T13:20:38.000Z - 9 months ago

Alvotech price target lowered to $10 from $28 at Northland


Deutsche downgrades Alvotech on AVT05 complete response letter

2025-11-04T10:00:10.000Z - 9 months ago

Deutsche downgrades Alvotech on AVT05 complete response letter


Alvotech downgraded to Hold from Buy at Deutsche Bank

2025-11-04T01:05:28.000Z - 9 months ago

Alvotech downgraded to Hold from Buy at Deutsche Bank


Alvotech falls -34.2%

2025-11-03T17:05:42.000Z - 9 months ago

Alvotech falls -34.2%


Toffik72
Toffik72 Jul. 15 at 5:37 AM
$ALVO Swedish SEB bank believes it is possible that Alvotech could raise its full-year guidance when it reports its second-quarter results. https://www.placera.se/telegram/alvotech-seb-ser-mojlighet-till-prognoshojning-for-2026-20260714 Here the translated version from swedish: STOCKHOLM (Nyhetsbyrån Direkt) – SEB believes it is possible that biosimilar company Alvotech could raise its full-year guidance when it reports its second-quarter results, although the bank's base-case expectation is that the guidance will remain unchanged. SEB wrote this in a research note in which it raised its price target to SEK 85 (approximately USD 8.85) from SEK 65 (approximately USD 6.75), while reiterating its Buy recommendation. With competitive pressures easing, SEB sees room for a positive re-rating of the stock, which it expects to occur over the next 12–18 months. For the full year 2026, Alvotech's guidance calls for: Total revenue of USD 650–700 million Adjusted EBITDA of USD 180–220 million
1 · Reply
Toffik72
Toffik72 Jul. 14 at 8:29 PM
$ALVO Interview with the CEO. https://insights.citeline.com/generics-bulletin/leadership/interviews/alvotech-seeks-launch-momentum-from-renewed-fda-push-LUAY3BMQQJHH3OZ3Z5DD7Y4UDM/
1 · Reply
JohnTill
JohnTill Jul. 14 at 3:49 PM
$ALVO Still taking it slow and added 50% to the position just now at 3.20-3.22. There is still a long way to the flood of positive news in Dec.+ and into 2027 but do not want to risk not have any position prior to this period. Will we see the 2s again?
1 · Reply
diggs24
diggs24 Jul. 14 at 3:26 PM
0 · Reply
Luc7777
Luc7777 Jul. 10 at 1:38 PM
$ALVO number one explanation is toxicity of unrevealed sharedealing. Not for sure but studied so many times...
0 · Reply
diggs24
diggs24 Jul. 9 at 9:31 PM
$ALVO As promised
1 · Reply
JohnTill
JohnTill Jul. 9 at 3:08 PM
$ALVO For anyone who missed it and wondering about the weakness. The $108 million convertible bond carried a conversion price of $5.9224, set at a 25% premium over the $4.7379 reference price. The bond includes a reset provision that kicks in if any equity raise or private placement is done. The most common design for these Nordic/European-style "reset on capital raise" clauses is to re-strike the conversion price at the new offering price plus the original premium — so $3.75 × 1.25 = $4.6875. I am betting this is what has been done. These bondholders hedge, which means the reset forced them to short an additional ~3–4 million shares to get back to delta neutral at the lower strike. On top of that, the reset adds roughly 5 million shares of dilution to the $108 million convert. Overall, I view the added cash as a positive and still believe we see that $8 gap filled in 2027 but short term, this explains the weakness. As posted, I sold out in the 4s and very slowly buying back.
1 · Reply
katkus
katkus Jul. 8 at 6:20 PM
$ALVO diluting the stock, any details about the most recent offering
0 · Reply
Stocksman45
Stocksman45 Jul. 7 at 9:27 PM
$ALVO Shares Outstanding by Year Reporting Date Shares Outstanding End of 2022. ~212 million End of 2023. ~290 million End of 2024 ~312 million End of 2025 312.0 million After June 2026 offering 390.4 million
2 · Reply
diggs24
diggs24 Jul. 7 at 2:24 PM
$ALVO Think I'll start buying back in at $3.25. The pop was nice and unexpected but the continued bleed was not expected.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jul. 6 at 9:23 PM
$ALVO 3:21 PM EDT, 07/06/2026 (MT Newswires) -- Alvotech(ALVO) is likely to report a "soft quarter" due to production disruptions tied to regulatory resubmissions, but is well positioned to benefit from the upcoming biosimilar loss of exclusivity opportunity, UBS said in a Q2 preview received on Monday. The company is scheduled to report its Q2 results on Aug.19. UBS lowered its Q2 forecasts to $106 million in revenue and $15 million in operating income from $146 million and $36 million, respectively. The brokerage said production resumed in June and expects a "significant step-up" in the second half. With the company's management reiterating confidence that the targeted Q4 approval and launch timeline remains on track across three assets, UBS said the risk/reward is skewed heavily to the upside. UBS reiterated its buy rating and price target of $6.
1 · Reply
Toffik72
Toffik72 Jul. 6 at 6:03 PM
$ALVO looks it will at least test 3,47 from 25.06, hope it gives an nice bounce.
1 · Reply
FlyingChemist01
FlyingChemist01 Jul. 6 at 4:28 PM
$ALVO I wonder for how long we will stay under 4$ to be honest, will be interesting months.
0 · Reply
Stocksman45
Stocksman45 Jul. 6 at 2:49 AM
$ALVO Key products and timing: Candidate Reference product Status Revenue importance AVT02 Humira (adalimumab) Commercial Already meaningful contributor AVT04 Stelara (ustekinumab) Commercial Growing revenue stream AVT03 Prolia/Xgeva (denosumab) Approved in Europe; U.S. pending Large opportunity AVT05 Simponi/Simponi Aria Europe approved; U.S. pending Potential first-mover advantage AVT06 Eylea (aflibercept) International launches underway; U.S. launch expected from late 2026 under settlement (One of the largest future drivers). AVT16/80 Entyvio (vedolizumab) EMA filing submitted Longer-term contributor
1 · Reply
Toffik72
Toffik72 Jul. 2 at 7:17 PM
$ALVO What will it take for biosimilars to fulfil their long-term potential in the US? Interesting interview with Alvotechs Head of Commercial Harshika Sarbajna https://pharmaboardroom.com/interviews/harshika-sarbajna-svp-commercial-global-alvotech/
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jul. 2 at 6:22 PM
$ALVO took some (again) but how many buying opps does one need
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jul. 1 at 2:08 PM
$ALVO seems like there is a seller putting a cap on this name the past few days i took some
1 · Reply
Toffik72
Toffik72 Jul. 1 at 9:37 AM
$ALVO Alvotech further strengthens liquidity by securing term loan facility of $75 million https://investors.alvotech.com/news-releases/news-release-details/alvotech-further-strengthens-liquidity-securing-term-loan
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 29 at 7:13 PM
$ALVO i've been on the fence last few trading days it may end up being along summer/fall but it seems they are headed in the right direction i'm still not crazy about the timing of the offering; but really liked that current major holders took a chunk of the shares sold @ 3.75
0 · Reply
Kosmokrat
Kosmokrat Jun. 28 at 4:50 PM
$ALVO will announce Q2 earnings on Aug-19, one day later host an earnings call. They will most likely update their guidance, I hope towards the upper end, or even beyond that. This could be a very positive signal for the SP, you better buy in July, if you plan to add shares below $4.
0 · Reply
Toffik72
Toffik72 Jun. 26 at 7:41 AM
$ALVO stock is pulling back after a strong rally is quite normal. With possible FDA approvals of AVT05 and AVT06 as big possible catlayst first earliest in Dec. With the decline from yesterday SP approached the first important support around $3.45–3.50. Hopefully will climb back above 3,75 soon... Has ALVO in the past anounced that, FDA has accepted the BLA-s? If not mistaken FDA has up to 60 days to determine whether a submission is sufficiently complete to file and begin the review clock?!
1 · Reply
JohnTill
JohnTill Jun. 25 at 7:18 PM
$ALVO I have been out of the stock since the 4s outside a just a few in the 3.70s last week. We are now finally testing that 50MA at 3.56 and just filled for a decent piece at 3.54 and will add from this point down or follow the bounce. I still believe that $8 gap will be filled and ALVO will get bought down the road in the double digits. I do not want to be sitting empty handed when that happens. However, Dec. product launch is still a long ways away and we have Sept/Oct to trade through so I am in no rush for a full position. Overall everything is point in the right direction and they are now flush with cash given cash flow in a few quarters.
2 · Reply